Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 14;9:683038. doi: 10.3389/fcell.2021.683038

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Navarro-Carrasco and Lazo.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

VRK1 knockdown prevents 53BP1 foci formation after TMZ and olaparib treatments in LN-18. (A) Left. Effect of siControl on 53BP1 foci formation induced by TMZ, olaparib and their combination. Right. Effect of the combination of siVRK1-02 and siVRK1-03 on 53BP1 foci formation induced by TMZ, olaparib and their combination. (B) Quantification of the effect of VRK1 depletion on 53BP1 fluorescence per nuclear area. Fifty cells per condition in triplicate were quantified. Field images shown in Supplementary Figure 9. NT: no treatment. Scale bar = 10 μm. ***p < 0.001. (C) Western blot showing the effect of VRK1. β-actin was used as load control.